Here's What You May Have Missed About Medtronic (MDT)

Shares of Health Care sector company Medtronic moved -0.7% today, and are now trading at a price of $81.52. The large-cap stock's daily volume was 2,139,465 compared to its average volume of 7,021,858. The S&P 500 index returned a 0.0% performance.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company is based in Dublin and has 95,000 full time employees. Its market capitalization is $108,390,408,192. Medtronic currently offers its equity investors a dividend that yields 3.3% per year.

27 analysts are following Medtronic and have set target prices ranging from $68.0 to $104.0 per share. On average, they have given the company a rating of buy. At today's prices, MDT is trading -9.62% away from its average analyst target price of $90.19 per share.

Over the last year, MDT's share price has increased by 6.4%, which represents a difference of -16.6% when compared to the S&P 500. The stock's 52 week high is $92.02 per share whereas its 52 week low is $68.84. With average free cash flows of $5.16 Billion that have been growing at an average rate of 2.2% over the last 6 years, Medtronic is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k)
2023 6,039,000 1,459,000 4,580,000
2022 7,346,000 1,368,000 5,978,000
2021 6,240,000 1,355,000 4,885,000
2020 7,234,000 1,213,000 6,021,000
2019 7,007,000 1,134,000 5,873,000
2018 4,684,000 1,068,000 3,616,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.